BBH: Mature Biotech Exposure, But Limited Growth Ahead [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
BBH's heavy concentration in Amgen, Gilead Sciences, and Vertex Pharmaceuticals exposes it to low growth and limited product diversification risks. Despite a low expense ratio, BBH underperforms peers on 10-year returns, dividend yield, and overall valuation, making it less compelling than broader healthcare ETFs. Patent expirations and insufficient R&D reinvestment threaten BBH's top holdings, further challenging its ability to sustain recent gains into 2026. TanyaJoy/iStock via Getty Images Investment Thesis VanEck Biotech ETF ( BBH ) warrants a hold rating due to the mixed factors impacting the fund's top holdings. While BBH's top-weighted companies have a proven track record of profitability, these holdings either lack the This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and i
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System LymphomaBusiness Wire
- Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- GILD's page on the SEC website